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qnrS1, in nontyphoidal salmonellae in 
the United Kingdom. These data are 
in contrast to those of recent studies 
in the United States and France, which 
show low incidences of qnrS genes in 
larger strain collections (9,10). The 
qnr phenotype is in contrast to resis-
tance mediated by mutations in the 
topoisomerase genes whereby 1 mu-
tation confers low-level resistance to 
ﬂ   uoroquinolones and full resistance 
to nalidixic acid. Our previous study 
demonstrated that qnrS1 was sufﬁ  -
cient to cause decreased susceptibility 
to ciproﬂ  oxacin in the absence of mu-
tations in gyrA (1). In this study, a qnr 
gene was sufﬁ  cient to increase the cip-
roﬂ  oxacin MIC to 0.38–0.75 μg/mL. 
In addition, a qnr gene contributed to 
high-level ciproﬂ  oxacin resistance in 
10 isolates, thereby potentially jeopar-
dizing ﬁ  rst-line treatment of vulnera-
ble patient groups with ciproﬂ  oxacin.
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Saksenaea 
vasiformis 
Infection, 
French Guiana 
To the Editor: The Zygomycetes 
are a class of ﬁ  lamentous fungi that are 
ubiquitous in the environment. Most 
of the species known to cause human 
or animal infections belong to a few 
genera within the order Mucorales. 
Saksenaea vasiformis, isolated from 
soil in India and described by Saksena 
in 1953, was reported to cause human 
infection for the ﬁ  rst time by Ajello et 
al. (1). We report a case of a cutane-
ous lesion caused by S. vasiformis in 
French Guiana.
A nonimmunocompromised 47-
year-old woman with a long history of 
non–type 1 diabetes mellitus, who had 
lived in French Guiana for many years, 
was admitted to Cayenne Hospital on 
November 18, 2005, with a cutaneous 
lesion of the abdominal wall and a fe-
ver that had lasted for 5 days before 
she was hospitalized. A skin biopsy 
specimen was obtained, and the ﬁ  rst 
surgical debridement was performed 
on day 4 of hospitalization. A diagno-
sis of zygomycosis was made after di-
rect examination and histopathologic 
examination of the tissue samples. 
Treatment was initiated on day 8, be-
ginning with liposomal amphotericin B 
and itraconazole for 10 days, followed 
by liposomal amphotericin B alone 
for 12 days. Persistence of necrotic 
tissues at the infection site required 
additional surgical debridement on 
day 10. Histopathologic examination 
of the resected tissues showed dam-
aged hyphae of zygomycetes. Reso-
lution of clinical signs was excellent. 
Additional biopsy specimens taken by 
the end of treatment on day 21 were 
negative for fungi by direct examina-
tion and culture. Finally, a cicatrix was 
formed.
Histologic examination of the 
initial excised tissues showed a local-
ized periumbilical cutaneous lesion of 
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14 cm × 13 cm. The skin was covered 
by a 1-mm layer of necrosis. The ne-
crosis extended into all the abdominal 
adipose tissue at the rectus abdominis 
muscle and linea alba. Microscopy 
examination showed extensive super-
ﬁ  cial mycotic proliferation, with wide 
and irregular ribbonlike nonseptate 
hyphae and right-angle branching. 
These hyphae extended toward the hy-
podermic fat tissues and were associ-
ated with a break in the cell membrane 
of adipocytes and with crystals inside 
the adipocytes. These lesions were as-
sociated with massive nonsuppurative 
vascular thrombosis.
Culture of tissues samples on 
Sabouraud-chloramphenicol-genta-
micin agar after 4 days at 30°C and 
37°C grew a white aerial mold, which 
covered the entire surface of the agar. 
Examination by microscopy showed 
nonseptate sterile hyphae typical of a 
zygomycete. The fungal isolate was 
sent to the National Reference Center 
for Mycology and Antifungals at the 
Institut Pasteur, Paris. Subcultures on 
different media including malt extract 
agar and potato dextrose agar grew 
sterile mycelia. The isolates were 
then cultured in nutritionally deﬁ  cient 
medium consisting of sterile distilled 
water supplemented with 0.05% ﬁ  lter-
sterilized yeast extract (Difco, Becton, 
Dickinson and Company, Sparks, MD, 
USA) solution for 7 days at 37°C (2). 
Typical  ﬂ   ask-shaped sporangia en-
abled identiﬁ  cation  of  S. vasiformis 
(Figure). Sporulation also occurred on 
Czapek agar after 7 days’ incubation 
at 37°C. 
Molecular identiﬁ  cation based on 
PCR ampliﬁ  cation and sequencing of 
rDNA internal transcribed spacer (ITS) 
regions was also performed. Brieﬂ  y, 
mycelia were grown in liquid Roswell 
Park Memorial Institute medium, and 
DNA was extracted as previously de-
scribed (3). Ribosomal DNA, includ-
ing the complete ITS1–5.8S-ITS2 
region, was ampliﬁ  ed with the fungal 
universal primer pairs V9D/LS266 (4) 
and ITS1/ITS4 (5), and both strands 
of PCR products were sequenced. 
The sequence has been deposited in 
GenBank (accession no. EU182902). 
Sequence alignment with the only S. 
vasiformis ITS sequence available in 
the GenBank database showed 82% 
similarity over 530 bp. This low de-
gree of sequence homology is prob-
ably reﬂ  ective of the need for further 
phylogenetic study of this genus. 
Sporulation on Czapek agar en-
abled preparation of a sporangiospore 
suspension used for antifungal suscep-
tibility testing. Sporangiospore sus-
pension was counted microscopically 
and adjusted to the required density. 
MICs, determined by the EUCAST 
reference microdilution method (6), 
after 48 h of incubation were >8, 2, 
>8, 0.5, and >8 μg/mL for ampho-
tericin B, itraconazole, voriconazole, 
posaconazole, and caspofungin, re-
spectively. The MIC of 0.5 μg/mL for 
posaconazole suggests the potential 
clinical utility of this agent.
S. vasiformis has been isolated 
from soil samples in different parts of 
the world (7). This fungus has been 
rarely responsible for human infec-
tions. A recent review (8), which did 
not include infrequently cited articles 
(9,10), found only 30 human cases. 
This scarcity may occur because the 
diagnosis is often based on histologic 
features and S. vasiformis does not 
sporulate in routine mycology media.
Due to zygomycetes’ lack of sus-
ceptibility to most of the antifungal 
agents, identiﬁ  cation of a zygomycete 
as the etiologic agent of an infection is 
essential for rapid and accurate man-
agement of the disease. Rare Zygo-
mycetes species such as S. vasiformis 
or Apophysomyces elegans should be 
suspected when a nonsporulating zy-
gomycete is isolated from an infected 
lesion. When this acute infection is 
suspected after examination of tissue 
by microscopy, the fungi should be 
cultured in speciﬁ  c culture media to 
induce sporulation or they should be 
identiﬁ  ed by molecular tools.
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Figure. Microscopic characteristics of the isolate of Saksenaea vasiformis cultured on 
Czapek agar. A) Typical ﬂ  ask-shaped sporangia (scale bar = 25 μm) containing B) smooth-
walled, rectangular sporangiospores (scale bar = 10 μm).LETTERS
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Q Fever in Young 
Children, Ghana
To the Editor: Recently, ex-
perts identiﬁ  ed Q fever, caused by the 
small, gram-negative bacterium Coxi-
ella burnetii, as an important underdi-
agnosed childhood disease (1). Stud-
ies on Q fever in children <5 years of 
age are scarce, especially with respect 
to sub-Saharan Africa. The only avail-
able study from Niger reports a sero-
prevalence of 9.6% (2). Throughout 
Africa, prevalence of Q fever in adults 
shows considerable variability and is 
highest in countries with prominent 
stockbreeding (3).
Clinical manifestations of Q fe-
ver in children are similar to those 
of malaria (1,4). In malaria-endemic 
areas, most fevers are attributed to 
Plasmodium falciparum infection and 
presumptively treated with expensive 
combination therapies (5). In this con-
text, other neglected fever-causing 
pathogens need to be given appropri-
ate consideration.
We studied the prevalence of Q 
fever antibodies in 219 randomly se-
lected children living in 9 rural villages 
of the Ashanti region, Ghana. Plasma 
was obtained by venous puncture from 
2-year-old children after they had par-
ticipated in a malaria control study 
and had been clinically monitored for 
21 months. Clinical, parasitologic, so-
cioeconomic, and Global Positioning 
System information was recorded as 
described elsewhere (6,7). In addition, 
158 healthy adult volunteers from the 
same area were included. Plasma was 
stored at –20°C until microimmuno-
ﬂ   uorescence assays (IFA) (Coxiella 
burnetii I+II, Vircell SL Microbiolo-
gists, Granada, Spain) were performed 
according to manufacturer’s instruc-
tions. To identify all children with 
Q fever titers, we regarded the fol-
lowing as positive ﬂ  uorescence reac-
tions to plasma dilutions: >1:64 for 
phase II immunoglobulin (Ig) G and 
>1:24 for phase II IgM with sensitiv-
ity (speciﬁ  city) of 97.2% (100%) and 
100% (56.3%), respectively. IgM test-
ing was only performed on IgG-posi-
tive children. Positive and negative 
controls were run on each IFA slide. 
Relative risks (RR) for characteristics 
of children were calculated by χ2 test; 
p<0.05 was considered signiﬁ  cant. In-
formed consent was obtained from all 
participants or their parents. The study 
protocol was approved by the com-
mittee on human research and publi-
cation, Kwame Nkrumah University 
of Science and Technology, Kumasi, 
Ghana.
Positive C. burnetii phase II IgG 
responses were observed in 37 (16.9%) 
of 219 children and 14 (8.9%) of 158 
adults (Figure, panels A and B). In 
comparison to adults, more children 
had IgG titers >64 (Figure, panels C 
and D). On the day of the serosurvey 
71 (32.4%) of 219 children had fever 
(measured body temperature >38°C or 
reported fever within the previous 48 
hours). Test outcome did not appear to 
be inﬂ  uenced by P. falciparum infec-
tion, since 4 of 37 IgG-positive children 
(23 of 182 IgG-negative children) had 
clinical malaria, 11/37 (62/182) had 
asymptomatic parasitemia, and 6/37 
(38/182) had fever without parasitemia, 
and there were no signiﬁ  cant differences 
between groups. The frequency of prior 
malaria episodes also did not inﬂ  uence 
antibody response. Three aparasitemic 
children had positive phase II IgM ti-
ters (24, 96, and 1,536; phase II IgG 64, 
64, and 4,096, respectively). The child 
with the high IgM and IgG titers was 
clinically ill with nonsevere C. burnetii 
pneumonia. This child was among 10 
(27%) of 37 phase II IgG-positive chil-
dren with detectable anti–C. burnetii 
phase I antibodies. Of all sociodemo-
graphic characteristics under consid-
eration, only maternal illiteracy was 
associated with positive phase II IgG 
testing (RR 2.1, 95% conﬁ  dence inter-
val 1.0–4.2, p<0.05).
A considerable proportion of 
Ghanaian children had anti–C. bur-
netii antibodies, which indicates that 
Q fever might be a common event in 
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Letters
Letters commenting on recent articles as 
well as letters reporting cases, outbreaks, 
or original research are welcome. Letters 
commenting on articles should contain no 
more than 300 words and 5 references; they 
are more likely to be published if submit-
ted within 4 weeks of the original article’s 
publication. Letters reporting cases, out-
breaks, or original research should contain 
no more than 800 words and 10 references. 
They may have one Figure or Table and 
should not be divided into sections. All let-
ters should contain material not previously 
published and include a word count.